Grants and Contributions:
Title:
Production and Evaluation of Multiple ADED-Enhanced ADCs
Agreement Number:
912889
Agreement Value:
$198,141.00
Agreement Date:
Sep 1, 2018 - Aug 31, 2019
Description:
This project will enable iProgen Biotech to produce and evaluate a number of different antibody-drug conjugates (ADCs) that are performance-enhanced by the firm's proprietary technology. The results of this project will allow the firm to identify a lead therapeutic drug candidate to take through IND-enabling preclinical development .
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Burnaby, British Columbia, CA V5A 4N4
Reference Number:
172-2018-2019-Q2-912889
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
826908816
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 10,000 dollars.
Amendment Date
Mar 29, 2019
Recipient's Legal Name:
iProgen Biotech Inc.
Federal Riding Name:
Burnaby North--Seymour
Federal Riding Number:
59002
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: